trending Market Intelligence /marketintelligence/en/news-insights/trending/htNMfSAL-PT6BOwfli9rFg2 content esgSubNav
In This List

Coloplast conducts strategic review of urology business

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Coloplast conducts strategic review of urology business

Coloplast A/S confirmed that it is conducting an unconditional strategic review of its interventional urology unit following a report that it was considering selling the business.

The Danish healthcare supplies company has hired advisers to consider a sale of the business for over $1 billion, according to some news reports.

The company said it will provide further information when it becomes available.

Coloplast's interventional urology business generated 967 million Danish kroner in revenue for the first six months of fiscal 2019, accounting for over 11% of Coloplast's sales for the period.

Coloplast develops intimate healthcare products, such as wound dressings and body waste collection devices.

As of June 4, US$1 was equivalent to 6.64 Danish kroner.